DASH
Repository logo
Communities & Collections
Browse DASH
DASH Stories
Statistics
  1. Home
  2. Harvard Division of Continuing Education
  3. DCE Theses and Dissertations
  4. Antibody-Conjugated Lipid Nanoparticles Could Enable Targeted Delivery to Long-Term Hematopoietic Stem Cells to Treat Blood Diseases

Antibody-Conjugated Lipid Nanoparticles Could Enable Targeted Delivery to Long-Term Hematopoietic Stem Cells to Treat Blood Diseases

Open/View files
Peer_Miranda_Thesis_May2026.pdf (2.03 MB)
Date
May 7, 2026
Author(s)
Peer, Miranda Rubin
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Peer, Miranda Rubin. 2026. Antibody-Conjugated Lipid Nanoparticles Could Enable Targeted Delivery to Long-Term Hematopoietic Stem Cells to Treat Blood Diseases. Masters Thesis, Harvard University Division of Continuing Education.
Abstract
Engineered RNA therapeutics enable modulation of gene expression, while offering a safer alternative to DNA based approaches, however clinical success largely depends on efficient and cell-specific delivery, as naked RNA is unstable in circulation. Lipid nanoparticles (LNPs) have become the leading non-viral vehicle for RNA delivery and have demonstrated clinical efficacy, including the well-known mRNA COVID-19 vaccines developed by Moderna and Pfizer. Although these advances are significant, conventional LNPs primarily localize to the liver after systemic administration, restricting their effectiveness for diseases that require delivery to tissues beyond the liver. Targeting long-term hematopoietic stem cells (LT-HSCs) could enable durable correction of blood disorders such as sickle cell disease, for which existing ex vivo therapies require costly manufacturing and are highly invasive. This work investigates antibody-conjugated LNPs (Ab-LNPs) to target LT-HSC specific surface markers to achieve selective in vivo delivery of gene-editing payloads. Through antibody selection, in vitro screening, in vivo biodistribution, and finally a durability study, this thesis aims to establish a scalable and less invasive gene therapy platform for hematologic diseases.
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service
URI
https://dash.harvard.edu/handle/1/42736841
Subjects

Antibody-conjugated L...

Gene Therapy

Hematologic diseases

Hematopoietic stem ce...

Lipid Nanoparticles (...

RNA therapeutics

Biology

Collection
DCE Theses and Dissertations
Metrics
Repository logo
  • CONTACT US
  • OSRDS
  • ABOUT DASH
  • DEPOSITING TO DASH
  • TERMS OF USE
  • REQUEST A WAIVER
  • TAKE DOWN POLICY
  • NAME CHANGE POLICY
  • HARVARD OA POLICIES
  • DASH SUBMITTER AGREEMENT
  • Accessibility
  • Privacy
Creative Commons License BY
Creative Commons Attribution 4.0 International License

Except where otherwise noted, this work is subject to a Creative Commons Attribution 4.0 International License,
which allows anyone to share and adapt our material as long as proper attribution is given.
For details and exceptions, see the Harvard Library Copyright Policy
©2024 Presidents and Fellows of Harvard College.